Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
refisolone
product4 mentionslast seen Nov 9, 2026
Intranasal pherine product candidate for treatment of vasomotor symptoms due to menopause.
Relationships 4
Relationship
Vistagen Therapeutics, Inc.developsrefisolone
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 9, 2026Vistagen Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
refisolone for vasomotor symptoms (hot flashes) due to menopause
- filingSEC EDGAROct 30, 2026Vistagen Therapeutics, Inc. 8-K: Item 2.05: Cost Associated with Exit or Disposal Activities; Item 8.01: Other Events
potential future development of its lead Phase 2 product candidates, itruvone for major depressive disorder and refisolone for menopausal hot flashes
- filingSEC EDGARSep 24, 2026Vistagen Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Vistagen's most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause
- filingSEC EDGARSep 22, 2026Vistagen Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause